Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Serine/threonine-protein kinase mTOR | ||
Ligand | BDBM50428118 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_944958 (CHEMBL2343997) | ||
Ki | 2.0±n/a nM | ||
Citation | Cheng, H; Li, C; Bailey, S; Baxi, SM; Goulet, L; Guo, L; Hoffman, J; Jiang, Y; Johnson, TO; Johnson, TW; Knighton, DR; Li, J; Liu, KK; Liu, Z; Marx, MA; Walls, M; Wells, PA; Yin, MJ; Zhu, J; Zientek, M Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett4:91-7 (2013) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Serine/threonine-protein kinase mTOR | |||
Name: | Serine/threonine-protein kinase mTOR | ||
Synonyms: | FK506-binding protein 12-rapamycin complex-associated protein 1 | FKBP12-rapamycin complex-associated protein | FRAP | FRAP 1 (mTOR) | FRAP1 | FRAP2 | MTOR | MTOR_HUMAN | Mammalian Target of Rapamycin (mTOR) | P42345 | RAFT1 | RAPT1 | Rapamycin and FKBP12 target 1 | Rapamycin target protein | Serine/threonine-protein kinase (mTOR) | mTORC2 | ||
Type: | Rapamycin target protein | ||
Mol. Mass.: | 288917.12 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P42345 | ||
Residue: | 2549 | ||
Sequence: |
| ||
BDBM50428118 | |||
n/a | |||
Name | BDBM50428118 | ||
Synonyms: | CHEMBL2331659 | US8791131, 134 | ||
Type | Small organic molecule | ||
Emp. Form. | C22H23N5O3 | ||
Mol. Mass. | 405.4497 | ||
SMILES | COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n([C@H]4CC[C@H](O)CC4)c3c2n1 |r,wU:20.20,wD:23.24,(32.03,-7.87,;33.36,-7.1,;34.69,-7.87,;34.69,-9.41,;36.03,-10.18,;37.36,-9.41,;37.36,-7.86,;36.02,-7.1,;38.7,-10.18,;38.69,-11.72,;40.02,-12.49,;41.35,-11.71,;42.69,-12.48,;44.03,-11.7,;44.01,-10.15,;45.14,-9.12,;46.65,-9.43,;44.51,-7.72,;45.28,-6.39,;42.99,-7.89,;42.18,-6.59,;40.64,-6.65,;39.83,-5.35,;40.55,-3.98,;39.73,-2.68,;42.09,-3.93,;42.9,-5.23,;42.68,-9.39,;41.35,-10.17,;40.02,-9.41,)| | ||
Structure |